New therapy to revert dysfunctional antibody responses during HIV-1 infection.
Level V
Where this comes from
- Record sourced from PubMed, PMID 20972328.
- Also identified by DOI 10.1172/JCI44872 and PMC identifier 2965000.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Individuals infected with HIV-1 progress to AIDS at different rates. Rapid progressors develop AIDS within 2-5 years of initial infection, compared with approximately 10 years in typical progressors. Progression to AIDS is associated with impaired humoral and cellular immunity. In this issue of the JCI, Titanji and colleagues report that activated memory B (mBAct) cells are depleted in SIV-infected macaques defined as rapid progressors. Depletion was mediated by programmed death-1 (PD-1) and resulted in reduction of antibody titers specific for SIV and bacterial antigens. Interestingly, blockade of PD-1 in infected animals protected B cells from apoptosis and increased levels of SIV-specific antibodies in blood. These findings pave the way for a new therapeutic strategy aimed at improving humoral immunity in HIV-1 infection.
Medical subject headings
- Antibody Formation
- HIV Infections
- HIV-1
- Immunologic Memory
- Simian Acquired Immunodeficiency Syndrome
- Simian Immunodeficiency Virus